56 results about "Lipid lowering drug" patented technology

A multi-system therapy which is adapted to treat diabetes, metabolic syndrome and obesity includes a hypoglycemic agent, a lipid lowering agent, a blood pressure lowering agent and, preferably, an anti-platelet agent. The composition can further include various vitamins and supplements such as vitamin B6, vitamin B12, arginin, a folate and other vitamins and minerals. Preferably, the hypoglycemic agent is a biguanide hypoglycemic agent without any additional hypoglycemic agent, making the composition suitable for treatment of individuals who are not hyperglycemic as well as those who are hyperglycemic.

The present invention provides a method of administering vitamin B6 related compounds for treatment of hypertriglyceridemia. Vitamin B6 related compounds include pyridoxal, pyridoxal-5′-phosphate, pyridoxamine, a 3-acylated analogue of pyridoxal, a 3-acylated analogue of pyridoxal-4,5-aminal, and mixtures thereof. Embodiments of the present invention also comprise co-administering a lipid lowering agent, such as a nicotinic acid, a fibrate, a HMG CoA reductase inhibitor, a cholesteryl ester transfer protein inhibitor, and combinations thereof.

The invention discloses mesoporous silica nanoparticles modified by nucleic acid aptamer targeting polyethylene glycol and a preparation method thereof. The method comprises the following steps: synthesizing mesoporous silica through TEOS(tetraethyl orthosilicate), CTAB(cetyltrimethyl ammonium bromide), alkali and water; modifying amino on the surface of the mesoporous silica through APTES (aminopropyltriethoxysilane) in an ethanol solution; and connecting the primary amine end group of the mesoporous silica to the carboxyl group of polyethylene glycol by reacting, connecting the terminal carboxyl group of a nucleic acid aptamer to the amine group of the polyethylene glycol on the mesoporous silica by reacting, and carrying, by the mesoporous silica nanoparticles, a lipid-lowering drug such as atorvastatin. The mesoporous silica nanoparticles and the preparation method thereof have the characteristics that the nucleic acid aptamer is bound with the biological target with high affinityand high specificity, the polyethylene glycol can improve the water dispersion and the sustained release capability of the carrier, and the mesoporous silica can carry hydrophilic and hydrophobic drugs of different molecular weights due to the characteristics of unique mesoporous structure, huge specific surface area, easy surface modification and the like.

The invention relates to a building method of a zebra fish hyperlipidemia model and application of the animal model to hyperlipidemia disease research and lipid-lowering drug screening. The building method of the zebra fish hyperlipidemia model mainly includes the steps of zebra fish selection, feeding of zebra fish by yolk powder, histochemical staining or fluorescent staining, image analysis and / or microwell plate analysis and statistical analysis. The building method has the advantages of simplicity, convenience, rapidity, economy, high efficiency, high throughput and the like, and the model can be used for hyperlipidemia disease research and lipid-lowering drug screening. The building method and application of the zebra fish bacterial infection model are of great significance to acceleration of research and development on lipid-lowering drugs and improvement on treatment of patients suffering from hyperlipidemia.

The invention provides a stereselective synthesis method for a lipid-lowering drug ezetimibe shown in formula I. The method comprises the following steps: a, P-fluorobenzoyl butyric acid shown in formula II reacts with a chiral auxiliary shown in formula III to obtain ketone shown in formula IV; b, under the existence of a chiral catalyst, the ketone shown in formula IV is reduced to chiral alcohol shown in formula V; c, chiral alcohol shown in formula V reacts with a silicyl protective agent to obtain a protected compound shown in formula VI, and then the compound shown in formula VI and imine shown in formula VII are subjected to addition and protecting groups are removed, so that a compound shown in formula VIII and a diastereomer thereof shown in formula IX are obtained, and through recrystallization with an appropriate solvent, an optically pure compound shown in formula VIII is obtained; d, the compound shown in formula VIII is protected with an acylation reagent, so that a compound shown in formula X is obtained, and amide shown in formula X is cyclized with a fluorinion catalyst, so that protected lactam shown in formula XI is obtained; then protecting groups are removed, and the ezetimibe shown in formula I is obtained.

The invention discloses application of Chinese herbal medicine turmeric extraction in the preparation of a slimming and lipid-lowering drug or a drug with a lipase activity inhibition effect. The invention overcomes the defects of low efficiency and large side effect of the existing clinical slimming drugs, in particular traditional Chinese medicines and provides the slimming and lipid-lowering drug with clear mechanism, scientific target point, small side effect and high clinical efficiency.

A concomitant agent to be used simultaneously or separately, comprising a combination of (a) 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine, a salt of the compound with an organic or inorganic and mono- or di-basic acid or a solvate thereof, and(b) at least one kind of active ingredient selected from the group consisting of an active ingredient of a pharmaceutical agent selected from (i) an antidiabetic drug, (ii) a lipid lowering drug, (iii) an antihypertensive drug, (iv) a therapeutic drug for diabetic complications, (v) an antiobesity drug, (vi) an antiplatelet drug and (vii) an anticoagulant, a pharmaceutically acceptable salt thereof and a solvate thereof.

The present invention relates to a stable solid oral pharmaceutical multi-component composition comprising combination of blood pressure lowering drugs with lipid lowering agent / s and optionally a platelet aggregation inhibitor in a single dosage form. The blood pressure lowering agents are selected from β-adrenergic receptor blocking agent, ACE inhibitor and diuretic. The lipid lowering agent is selected from HMG Co-enzyme-A reductase inhibitor. The pharmaceutical composition made as per present invention a) overcomes any drug-drug interactions, b) exhibits pharmacokinetic and pharmacodynamic profile of individual therapeutic agent, c) has minimal side effects. The invention provides multi-component composition (MCC) to increase adherences to therapy. The MCC as per present invention provides compositions that maintain activity of all active ingredients without significant increase in adverse event profile. The present invention further relates to a method of preparing the said pharmaceutical composition.

The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and / or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.

The invention discloses a lactobacillus probiotic strain. The preservation number of the strain is CGMCC NO. 12422, and the preservation date is May, 6th, 2016. The 16S rRNA sequence of the strain is shown as SEQ ID NO: 2. The invention also discloses an application of the strain in preparing a lipid-lowering drug, food and a healthcare product. The strain is harmless to animals and has effects of regulating and lowering blood fat.

The present invention provides a method of administering vitamin B6 related compounds for treatment of hypertriglyceridemia. Vitamin B6 related compounds include pyridoxal, pyridoxal-5′-phosphate, pyridoxamine, a 3-acylated analogue of pyridoxal, a 3-acylated analogue of pyridoxal-4,5-aminal, and mixtures thereof. Embodiments of the present invention also comprise co-administering a lipid lowering agent, such as a nicotinic acid, a fibrate, a HMG CoA reductase inhibitor, a cholesteryl ester transfer protein inhibitor, and combinations thereof.

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. The first non-statin lipid lowering agent is an agent that inhibits cholesterol uptake (e.g. ezetimibe) and the second non-statin lipid-lowering agent is an inhibitor of microsomal triglyceride transfer protein (e.g. lomitapide). The combination therapy is useful in treating hypercholesterolemia, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

Functional beverages and compositions are provided that suppress allergic rhinitis and prevent and treat hyperlipemia and related diseases thereof i.e. arteriosclerosis, obesity and liver diseases. The O-methylated catechin expressed by the chemical formula (1) shown below is included in a constitutive effective amount as an allergic rhinitis-suppressing drug and a lipid-lowering drug; [in which R1, R2, R3 and R4 are each independently a hydrogen atom or a methyl group, X1 and X2 are each independently a hydrogen atom or a hydroxy group.]

Provided are pharmaceutical compositions and methods for preventing or reducing niacin-induced flushing, where the pharmaceutical compositions comprise an aspirin component and a niacin component having different release profiles. Also provided are methods and compositions for preventing or reducing niacin-induced flushing, where the compositions comprise niacin, aspirin and a lipid-lowering drug other than niacin.

The invention provides a synthetic method of lipid-lowering drug ciprofibrate. The synthetic method comprises the following steps: catalyzing reaction of p-hydroxy benzaldehyde and propane diacid in a mixed solvent by virtue of alkali, so as to generate p-hydroxystyrene; catalyzing reaction of p-hydroxystyrene, acetone, chloroform and alkali by virtue of a phase transfer catalyst, so as to generate an intermediate 2-methyl-2-(4-vinylphenoxy)propionic acid; and reacting 2-methyl-2-(4-vinylphenoxy)propionic acid with TiCl4, Mg and CCl4, so as to generate ciprofibrate. The synthetic method has the beneficial effects that the reaction route is short, the raw materials are cheap and easily available, reaction conditions are mild, the energy consumption is reduced, and the production cost is lowered; the post-processing step is simple, the emission of three wastes is reduced, and the method is environment-friendly and safe. Compared with routes of predecessors, the synthetic method has the advantages that the reaction selectivity and conversion rate of the route are relatively high, the wasting of the raw materials is reduced, and the economical efficiency is relatively high.

The present invention relates to a combined pharmaceutical formulation, which is such designed that the release of each ingredient may be controlled to a predetermined release rate by applying the principle of the so-called chronotherapy, where drugs are administered in such a way that the activities of the drugs are expressed at intervals. The formulation of the present invention comprises statin-based lipid-lowering agent and dihydropyridine-based calcium channel blocker that affects cytochrome P450 enzyme as active ingredients, and is such constituted that the release rates of the aforementioned ingredients are different, thus preventing antagonism and side effects, while maintaining the synergistic effect, which leads to the convenience in medication.

The invention belongs to the technical field of extraction of a traditional Chinese medicine, and particularly relates to a method for extracting epiberberine and application thereof. The invention aims at solving the technical problem of providing new use of the epiberberine. The invention provides use of the epiberberine in preparation of a lipid-lowering drug. The invention also discloses use of the epiberberine in preparation of a drug for preventing or treating obesity. The invention also provides use of the epiberberine in preparation of an antioxidant drug. The invention also provides use of the epiberberine in preparation of a drug for preventing or treating atherosclerosis. The invention also provides an extraction method of the epiberberine. The method can be applied to preparation of the lipid-lowering drug, the antioxidant drug, the drug for preventing or treating atherosclerosis, the drug for preventing or treating obesity, and the like.

The present invention discovers the usefulness of Asystasia gangetica to health and industry, and obtains specific utilization methods and objects. On the basis of finding that the water extract of Viola violet leaves has antidiabetic effect, blood cholesterol suppressing effect and neutral fat suppressing effect, lactic acid bacteria proliferation promoting effect, and food flavor improving effect, as a solution, the present invention relates to its Application of antidiabetic agent, serum lipid lowering agent, and lactic acid bacteria proliferation promoter; application in food and animal feed; drying method of Viola chinensis leaves and the dried product obtained by the manufacturing method and its application in food; Application of Viola extract in the manufacture of fermented food.

The invention discloses application of Chinese herbal medicine turmeric extraction in the preparation of a slimming and lipid-lowering drug or a drug with a lipase activity inhibition effect. The invention overcomes the defects of low efficiency and large side effect of the existing clinical slimming drugs, in particular traditional Chinese medicines and provides the slimming and lipid-lowering drug with clear mechanism, scientific target point, small side effect and high clinical efficiency.

The invention discloses a liver-protecting kidney-strengthening detoxifying lipid lowering drug and a preparation method thereof, the liver-protecting kidney-strengthening detoxifying lipid lowering drug is composed of the following components by weight: 10-25% of mushrooms polysaccharide, 15-30% of coriolus versicolor polysaccharide, 15-30% of ganoderma lucidum polysaccharide, 10-25% of lycium barbarum polysaccharides, and 15-30% of red date polysaccharide. The mushrooms polysaccharide, coriolus versicolor polysaccharide, ganoderma lucidum polysaccharide, lycium barbarum polysaccharides and red date polysaccharide are processed into fine powder, proportionally mixed evenly, and processed by drying and sterilization into Chinese patent powder, the sterilized and evenly mixed Chinese patent powder is packed into a capsule tube instrument for sealing to obtain a capsule agent. The liver-protecting kidney-strengthening detoxifying lipid lowering drug has the advantages of simple process, fine and pure product, low cost, natural raw material plant, no any toxic and side effects, no addition of add any chemicals and excitants, people immune function can be enhanced, physical fitness can be improved, the liver-protecting kidney-strengthening detoxifying lipid lowering drug has the effects of protecting liver, strengthening kidney, lowering blood lipid and detoxifying, has remarkable medical and health care effects, ad can make people far away from sub-health.

The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and a medicinal application thereof. Provided in the invention is a chimeric antibody and a humanized antibody, both comprising a CDR of the PCSK9 antibody, and a pharmaceutical composition comprising the PCSK9 antibody and an antigen-binding fragment thereof, and an application of the PCSK9 antibody as a lipid-lowering agent. The invention specifically relates to an application of a humanized PCSK9 antibody for preparing a pharmaceutical drug to treat a PCSK9-induced disease or symptom.

The invention relates to superfine powder of a Fibrates lipid-lowering drug and a preparation method therefor. The Fibrates lipid-lowering drug is a main therapeutic drug for resisting hyperlipidemia, and due to influence resulting from factors such as relatively poor water solubility and the like, the bioavailability of the Fibrates lipid-lowering drug is not high. The method for preparing the superfine powder of the Fibrates lipid-lowering drug, provided by the invention, comprises the steps of applying ultrasonic waves, of which the frequency is 10kHz to 500kHz, the power is 1mW to 5,000W and the sound intensity is 0.1mW / cm<2> to 500W / cm<2>, to a Fibrates lipid-lowering drug containing homogeneous solution so as to rapidly obtain Fibrates lipid-lowering drug crystals, and then, carrying out normal operations such as solid collecting, washing, drying and the like, thereby directly obtaining the superfine powder of the Fibrates lipid-lowering drug. According to the superfine powder prepared by the method, the bioavailability of the drug is improved, the dosage of the drug is reduced, the solubility of the drug is improved, and the drug absorption can be enhanced, so that the application is wider.

The invention relates to extractive of chickweed flavone glycoside, containing apigenin-6-C-Beta-D-galactose-8-C-Alpha-L-arabinoside and apigenin-6-C-Alpha-L-arabinoside-8-C-Beta-D-galactoside. The invention also relates to the extraction method of the chickweed flavone glycoside extraction, the drug compound containing the extractive and the purpose for preparing lipid lowering drug.

A pharmaceutical composition comprising losartan or a pharmaceutically acceptable salt thereof, which is capable of treating or preventing side effects such as muscle toxicity caused by administering a statin-based lipid-lowering drug, and a pharmaceutical combination composition comprising a statin drug and a losartan drug as active ingredients are provided. The pharmaceutical composition comprising losartan or a pharmaceutically acceptable salt thereof provides an effect on treating or preventing muscle-related side effects caused by administration of a statin drug for treating hyperlipidemia, as well as an intrinsic pharmacological effect for treating or preventing hypertension. When administered along with a statin drug in sequence or co-administered at the same time with the statin drug, the pharmaceutical composition can exhibit an effect of effectively or significantly decreasing or preventing side effects such as muscle toxicity.

The present invention belongs to the technical field of drugs, and relates to a lipid-lowering drug ezetimibe compound. The lipid-lowering drug ezetimibe compound is measured by Cu-K alpha ray to obtain an X- ray powder diffraction pattern shown in Figure 1, the lipid-lowering drug ezetimibe compound has good liquidity, and a tablet prepared from the lipid-lowering drug ezetimibe compound has high dissolution, low impurity content, and good stability.

The invention provides momordica grosvenori root bionic extracts and a preparation method and application thereof. The preparation method comprises the steps of drying and pulverizing the roots of momordica grosvenori to obtain the root powder of the momordica grosvenori; mixing with bionic extract liquid, extracting, filtering, concentrating, and collecting concentrated solution; mixing the concentrated solution with ethyl acetate-butyl acetate solution, extracting, and removing solvent by rotary evaporation to obtain white powder which is the bionic extracts of the momordica grosvenori roots. The momordica grosvenori root bionic extracts, stachyodes lindl, cordyceps militaris, purslane, platycodon grandiflorum, buckwheat and auxiliary materials are taken to prepare descendens blood fat drugs. The momordica grosvenori root bionic extracts have an obvious effect of lowering blood fat.

The invention provides an oleanolic acid type saponin compound prepared by arlia elata extraction, separation and purification and having a specific structure. It is found that when the compound is used separately, the compound has remarkable weight-losing and lipid-lowering effects, and the effects are superior to the effect of its aglycone analogue oleanolic acid. When the compound is used withfructo-oligosaccharide, the compound and the fructo-oligosaccharide cooperate with each other and produce a joint action in specific proportion, so that the drug composition has a remarkable weight-losing effect, the weight-losing effect of the composition is superior to the weight-losing effect of a single compound, and the drug composition has a synergistic effect. In addition, the drug composition has the remarkable weight-losing and lipid-lowering effects and has a synergistic effect, the lipid-lowering effect of the drug composition is remarkably superior to the lipid-lowering effect of asingle compound.

The invention discloses an application of asanicula astrantiifolia wolff extract in preparation of a blood fat reducing drug, which belong to the technical field of blood fat reducing medicines. The sanicula astrantiifolia wolff extract is one or more of a sanicula astrantiifolia wolff alcohol extract, a sanicula astrantiifolia wolff petroleum ether part and a sanicula astrantiifolia wolff ethyl acetate part; a preparation method of the sanicula astrantiifolia wolff alcohol extract comprises the following steps: crushing dry rhizomes of sanicula astrantiifolia wolff by adopting a crusher, sieving the material, adding a C1-C4 alcohol solution with the volume percentage of 20-100%, extracting the material for 0.5-2 hours, centrifuging, taking a supernate, carrying out rotary evaporation, andconcentrating the material to obtain the sanicula astrantiifolia wolff alcohol extract. Compared with the prior art, the sanicula astrantiifolia wolff alcohol extract provided by the invention has the properties of high safety and good lipid-lowering effect, and can be applied to medicines, foods or functional foods for preventing and adjunctively treating obesity, alcoholic fatty liver, non-alcoholic fatty liver, type 2 diabetes, metabolic syndrome, coronary heart disease and atherosclerotic diseases.

The present invention is directed to a composition and method for the treatment of hyperlipidemias by targeting Microsomal triglyceride transfer protein (MTP). In particular, the present invention is directed to a combination of at least one MTP inhibitor and at least one lipid-lowering agent, both in an amount effective to treat hyperlipidemias.